Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

Related Keywords

Virginia ,United States ,American ,Goldschmidth Daratumumab ,Shaji Kumar ,Mark Wildgust ,Christie Corbett ,Global Medical Affairs ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,Division Of Hematology ,National Comprehensive Cancer Network ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Department Of Internal Medicine ,Drug Administration ,International Staging System ,Exchange Commission ,Companies Of Johnson ,Johnson ,Weiselk Health ,American Society ,Internal Medicine ,Vice President ,Janssen Research ,New England Journal ,Lancet Oncology ,Janssen Biotech ,National Comprehensive Cancer ,Interference With Serological ,With Determination ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Plus Lenalidomide ,Versus Lenalidomide ,Transplant Ineligible Patients ,Newly Diagnosed Multiple Myeloma ,Updated Analysis ,Hematology Annual ,With Newly Diagnosed Multiple Myeloma ,Clinical Assessment ,Key Subgroups ,Related Quality ,Frail Transplant Ineligible Patients ,Subgroup Analysis ,Prescribing Information ,Accessed December ,Statistics About Multiple Myeloma ,The Janssen Pharmaceutical Companies Of Johnson Amp ,